Filing search / Incannex Healthcare Limited / "Social"

8-K

EX-10.3

IXHL Incannex Healthcare Limited

21 Oct 24

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

4:35pm

) (Address) (Social Security or Tax Identification No.) The signature on this Assignment of Warrant must correspond to the name as written upon the face

10-K

2024 FY

EX-4.2

IXHL Incannex Healthcare Limited

30 Sep 24

Annual report

7:30am

-Mail Address: Social Security or Other Taxpayer Identification Number of Assignee: SIGNATURE GUARANTEED BY: Signatures must be guaranteed … Holder Contact Information of Registered Holder: Name: Phone: Mailing Address: E-Mail Address: Social Security or Other Taxpayer Identification

10-K

2024 FY

EX-19.1

IXHL Incannex Healthcare Limited

30 Sep 24

Annual report

7:30am

, or business or social acquaintances. Also, legal rules govern the timing and nature of our disclosure of material information to outsiders or the public

10-K

2024 FY

IXHL Incannex Healthcare Limited

30 Sep 24

Annual report

7:30am

in social, occupational and other functioning, according to the National Institute of Mental Health (“NIMH”). GAD is the most common anxiety disorder … contain cannabinoid and psychedelic substances that may generate public controversy. Political and social pressures and adverse publicity could lead

8-K

EX-10.1

IXHL Incannex Healthcare Limited

10 Sep 24

Entry into a Material Definitive Agreement

7:30am

of the within Warrant. Dated: ______________ (Signature) * (Name) (Address) (Social Security or Tax Identification No.) The signature on this Assignment

8-K

EX-10.2

ujdo11l

10 Sep 24

Entry into a Material Definitive Agreement

7:30am

8-K

EX-99.1

hdfycp

5 Aug 24

FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed

8:15am

S-1/A

btezx8o

17 Jul 24

IPO registration (amended)

8:47am

S-1

a7x0uguv jlqwv1q

3 Jul 24

IPO registration

6:29am

8-K

EX-99.1

alipo28 3i8v

28 Feb 24

Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

7:42am

8-K

EX-14.1

twtwz2bz55 y5d2rslzm

29 Nov 23

Entry into a Material Definitive Agreement

4:36pm

6-K

EX-99.1

232tt4i

1 Sep 23

Report of Foreign Private Issuer

8:43am

20-F

EX-4.11

m3b3cr8zc 0sbp

28 Oct 22

Annual report (foreign)

6:31am

6-K

EX-99.1

lat8b

12 May 22

Report of Foreign Private Issuer

9:25am